Cantor Fitzgerald Expects Lower Earnings for Krystal Biotech

Key Points

• Cantor Fitzgerald has reduced its FY2025 earnings per share (EPS) forecast for Krystal Biotech from $4.85 to $4.79, while the consensus estimate remains at $6.14.
• Several analysts maintain a "buy" rating for the stock, with price targets ranging from $166.00 to $240.00, indicating positive sentiment despite the downgraded EPS forecast.
• Krystal Biotech reported strong recent earnings, with $1.29 EPS for the quarter, surpassing the estimated $1.08.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Krystal Biotech in a research report issued on Tuesday, August 5th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $4.79 per share for the year, down from their prior estimate of $4.85. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. Cantor Fitzgerald also issued estimates for Krystal Biotech's FY2026 earnings at $7.35 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million.

A number of other analysts also recently issued reports on the company. Bank of America dropped their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Citigroup reiterated a "neutral" rating and set a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday. Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Finally, Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and a consensus target price of $210.22.

Krystal Biotech Stock Performance

Krystal Biotech stock traded up $2.56 during midday trading on Wednesday, hitting $138.66. 332,066 shares of the company's stock were exchanged, compared to its average volume of 422,365. The company has a market cap of $4.01 billion, a P/E ratio of 28.18 and a beta of 0.70. The stock has a 50-day moving average price of $141.94 and a two-hundred day moving average price of $155.36. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84.

Insider Activity

In related news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the transaction, the insider owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers lifted its stake in shares of Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company's stock valued at $597,000 after acquiring an additional 2,255 shares during the last quarter. SG Americas Securities LLC increased its stake in Krystal Biotech by 860.9% in the 2nd quarter. SG Americas Securities LLC now owns 12,607 shares of the company's stock worth $1,733,000 after purchasing an additional 11,295 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Krystal Biotech by 7.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,529 shares of the company's stock valued at $897,000 after purchasing an additional 472 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Krystal Biotech by 3.3% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,600 shares of the company's stock valued at $770,000 after purchasing an additional 180 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company's stock worth $85,174,000 after purchasing an additional 7,194 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).